The latest progress of stamp duty in Hong Kong has come!The latest news of personal pension fund, incremental funds are coming!Statement: Personal opinion, for reference only!
If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".At present, there is nothing wrong with the medium and long-term trend, so don't worry too much. Strategically, we will continue to watch more. Tactically, we will follow the trend and take the initiative step by step.
Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".
Strategy guide
12-13
Strategy guide
12-13
Strategy guide 12-13